Quantcast

Latest Multi-drug-resistant tuberculosis Stories

2009-06-03 16:00:00

Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB MECHELEN, Belgium, June 3 /PRNewswire/ -- Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the addition of TMC207 for eight weeks to a 5-drug background...

2009-04-27 06:00:00

Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European clinicians will have access to a rapid test that can simultaneously identify Mycobacterium tuberculosis (MTB) and resistance to rifampicin (RIF), a common first-line...

e171a821faa7a10015db7cd86436e2431
2009-04-16 11:22:34

Countries in the former Soviet Union and many regions of China are facing an epidemic of multi-drug resistant tuberculosis, according to a new report based on data from 90,000 patients in 83 countries. The analysis took place over the period of 2002-2007 and concluded that one-in-nine of the estimated nine million yearly reported cases of tuberculosis were resistant to at least one drug. Scientists define multi-drug resistant tuberculosis as not responding to at least two anti-TB...

f6152e3f54a6a323968cc17186718df7
2009-04-03 10:00:00

According to a study reported in The Lancet on Saturday, a new antibiotic has passed a key phase in a test of drugs aimed at shortening the time to cure tuberculosis, offering a potential boon in the fight against TB.The standard treatment for TB takes up to six months, which is a time that is so long that many patients abandon therapy because they believe to be cured when the symptoms are no longer felt. This results in the patients not completely being cleared of the germ that causes TB,...

2009-03-30 11:37:12

The discovery of a large number of slow-growing Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB), in the lungs of TB patients could be an important step forward in the design of new anti-TB drugs.Until now it was thought that M. tuberculosis bacteria in the lungs of TB patients were rapidly multiplying. However recent research by Dr Simon Waddell and colleagues from St George's University of London and the University of Leicester, using gene chips to look at how TB bacteria...

a71ecb642967620dbd02550e7e2102b61
2009-03-24 14:50:00

Disease experts claim that efforts to fight HIV and tuberculosis must be paired in order to be most effective. In recognition of World TB Day, the World Health Organization (WHO) released new findings to show that co-infection of TB among HIV patients is nearly twice as big as previously considered. In 2007, there were at least 1.37 million cases of HIV-positive TB "” or nearly 15 percent of the total incident cases. That figure doubles that of the previous estimates, WHO said. "A...

2009-03-24 09:11:00

WASHINGTON, March 24 /PRNewswire-USNewswire/ -- Statement from Stephen J. Nolan, Chairman of the American Lung Association: One hundred and five years after Dr. Edward Livingston Trudeau founded our health organization and dedicated it to eradicating Tuberculosis (TB), the American Lung Association joins thousands of individuals around the globe in celebrating 2009 World TB Day. Today, we recognize the lives and struggles of people affected by TB including women, men and children who have...

2009-03-24 06:00:00

SUNNYVALE, Calif.March 24 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced details of technology expected to revolutionize the speed of diagnosis of Mycobacterium tuberculosis (TB) and the resistance to common drug treatment for the disease. The new test technology, developed in partnership with Foundation for Innovative New Diagnostics (FIND) and the University of Medicine and Dentistry of New Jersey (UMDNJ), and funded by the National Institute of Allergy &...

4abcb7deff5aee25b28ab1b4e40e4e941
2009-02-26 16:36:42

U.S. researchers said on Thursday that two existing drugs used in combination appear to offer great promise against the most dangerous form of tuberculosis, Reuters reported. Doctors say the combination of AstraZeneca's MERREM I.V., also called meropenem, and clavulanate, sold by GlaxoSmithKline in combination with amoxicillin as the drug Augmentin, killed laboratory-grown strains of TB in clinical trials. Researchers wrote in the journal Science that the combination worked in lab dishes...

2009-01-23 14:36:31

A four-month treatment with the drug rifampin is better tolerated for tuberculosis than the nine-month treatment of isoniazid, Canadian researchers said. Dr. Dick Menzies of the McGill University said patients who are infected with the latent form of TB show no symptoms and are not contagious, yet they pose the biggest challenge when it comes to controlling the disease. Patients who currently receive a diagnosis of latent TB are treated for nine months with daily doses of isoniazid;...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related